Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label recurrent ovarian cancer. Show all posts
Showing posts with label recurrent ovarian cancer. Show all posts
Tuesday, May 01, 2012

Medscape: Bevacizumab Benefits Patients With Recurrent Ovarian Cancer (bevacizumab plus carboplatin and gemcitabine followed by bevacizumab)

›
Bevacizumab Benefits Patients With Recurrent Ovarian Cancer
Sunday, April 29, 2012

paywalled: PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer.

›
PET/CT scanning guided intensity-modulated radi... [Eur J Radiol. 2012] - PubMed - NCBI Abstract OBJECTIVE: This study was under...
Thursday, March 08, 2012

open access: Nature Reviews: Key Advances in Medicine - Ovarian Cancer/Markman page 15-16

›
Key Advances in Medicine (book) Nature Reviews Clinical Oncology  (page 15)S11 ovarian cancer | Mutations and non-inferiority analyses s...
Saturday, February 11, 2012

press release: The Clearity Foundation - Molecular profiling reveals differences between primary and recurrent ovarian cancers

›
Analysis of tumor specimens uncovers changes in biomarker expression that may have implications for therapy selection for women with rec...
Wednesday, July 13, 2011

full free access: Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

›
Sunday, May 08, 2011

abstract: HIPEC (hyperthermic intraoperative intraperitoneal chemotherapy) in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome.

›
Monday, June 28, 2010

Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough? -- Cannistra 28 (19): 3101 -- Journal of Clinical Oncology

›
Note: speaks about PFS vs OS (progression free survival; overall survival); PLD and Trabectedin (Yondelis) study (Monk); ICON4 and more
Thursday, June 03, 2010

It's a choice to move forward: women's perceptions about treatment decision making in recurrent ovarian cancer

›
Abstract OBJECTIVE: This research explores the treatment decision-making (TDM) experiences of women with recurrent ovarian cancer (ROC) wi...

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. (multinational study)

›
Note : Trabectedin is also known as Yondelis PURPOSE The objective of this study was to compare the efficacy and safety of trabectedin plu...
Tuesday, April 27, 2010

Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer

›
2 comments:
Saturday, February 06, 2010

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

›

Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial

›
Conclusion The combination of PLD and continuous IFO is a feasible and efficient treatment in patients with relapsed ovarian cancer, esp...